Aug 01, 2025
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
Jul 09, 2025
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
Feb 20, 2025
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
Jan 10, 2025
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
Sep 23, 2024
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Sep 12, 2024
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
May 01, 2024
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
Jan 18, 2024
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
Sep 22, 2020
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
Jun 22, 2020
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
Apr 07, 2020
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
Dec 11, 2019
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
Nov 25, 2019
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
Sep 12, 2019
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
May 20, 2019
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
May 08, 2019
New positive data from phase IIa trial in brain cancer patients
May 08, 2019
Kazia calls for greater awareness of the deadliest gynecological cancer in the US
Apr 01, 2019
Kazia Presents Positive Cantrixil Phase I Data at AACR Conference
Oct 29, 2018
Progress Update on GDC-0084 Program
Oct 22, 2018
Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer